Literature DB >> 22848257

Survival of untreated advanced colorectal cancer patients.

G P Stathopoulos1.   

Abstract

Colorectal cancer has specific biological characteristics that distinguish it from other malignancies. One such characteristic is its slow growth in patients in advanced stages. For the past 15 years, no effective systemic treatment has been available in clinical practice. The present study involved a retrospective evaluation of patients with advanced colorectal cancer in order to assess the median and overall survival of patients. Concurrently, the study aimed to describe the biological characteristics of this slow-growing disease and the quality of life of the patients. The key characteristic of this patient group was the lack of any systemic treatment. The study included 40 patients (25 male and 15 female, median age 67 years) who were evaluated between 1993 and 1996. Only supportive treatment was provided. One patient underwent 2 cycles of chemotherapy. Liver surgery was unsuccessfully performed on 3 patients. Two patients underwent radiofrequency once and 2 had intra-arterial treatment, also once. The results showed the median survival of patients to be 24 months (range 16-42). One-year survival was found to be 65% while the 2-year survival was found to be 25%. A satisfactory quality of life was also observed. In conclusion, colorectal cancer is a slow-going malignancy, as indicated by the long-term survival of patients and the biological characteristics of the tumor.

Entities:  

Year:  2011        PMID: 22848257      PMCID: PMC3406332          DOI: 10.3892/ol.2011.310

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

1.  Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

Authors:  D J Sargent; D Niedzwiecki; M J O'Connell; R L Schilsky
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 3.  Efficacy of oxaliplatin in the treatment of colorectal cancer.

Authors:  M L Rothenberg
Journal:  Oncology (Williston Park)       Date:  2000-12       Impact factor: 2.990

4.  Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.

Authors:  W Scheithauer; G V Kornek; M Raderer; J Valencak; G Weinländer; M Hejna; K Haider; W Kwasny; D Depisch
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

5.  Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.

Authors:  George P Stathopoulos; Sotiris K Rigatos; John G Stathopoulos; John P Xynotroulas; Evangelini Dimou
Journal:  Am J Clin Oncol       Date:  2005-12       Impact factor: 2.339

6.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Authors:  D Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; C A Topham; L Awad; C Jacques; P Herait
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

7.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Authors:  P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

8.  Adjuvant therapy of colon cancer--results of a prospectively randomized trial.

Authors: 
Journal:  N Engl J Med       Date:  1984-03-22       Impact factor: 91.245

9.  Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.

Authors:  G Francini; R Petrioli; L Lorenzini; S Mancini; S Armenio; G Tanzini; S Marsili; A Aquino; G Marzocca; S Civitelli
Journal:  Gastroenterology       Date:  1994-04       Impact factor: 22.682

10.  Long-term survival of patients with advanced colorectal cancer may not be due to the response to chemotherapy.

Authors:  George P Stathopoulos; Sotiris K Rigatos; Nicos A Malamos; John G Stathopoulos; Panayiota Thallasinou; Ekaterini Papazachariou; Fotini Antoniou; Emmanuel Kondopodis; John Xynotroulas
Journal:  Oncol Rep       Date:  2004-12       Impact factor: 3.906

View more
  3 in total

1.  Cancer Treatment: The Cost Factor.

Authors:  S Smith
Journal:  West Indian Med J       Date:  2014-08-29       Impact factor: 0.171

2.  Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification.

Authors:  Umut Disel; Alexis Germain; Bahar Yilmazel; Huseyin Abali; Filiz Aka Bolat; Roman Yelensky; Julia A Elvin; Doron Lipson; Juliann Chmielecki; Kai Wang; Philip J Stephens; Jeffrey S Ross; Vincent A Miller; Siraj M Ali; Thomas J George
Journal:  Oncoscience       Date:  2015-07-01

3.  A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer.

Authors:  Manabu Kodama; Kiyotaka Oshikawa; Hideyuki Shimizu; Susumu Yoshioka; Masatomo Takahashi; Yoshihiro Izumi; Takeshi Bamba; Chisa Tateishi; Takeshi Tomonaga; Masaki Matsumoto; Keiichi I Nakayama
Journal:  Nat Commun       Date:  2020-03-17       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.